Detalles de la búsqueda
1.
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.
Int J Cancer
; 154(6): 1043-1056, 2024 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37994647
2.
HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
Br J Cancer
; 130(8): 1316-1323, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38347094
3.
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
BMC Cancer
; 24(1): 436, 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38589856
4.
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Br J Cancer
; 128(7): 1391-1399, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36759721
5.
IMMUNOREACT 6: weak immune surveillance characterizes early-onset rectal cancer.
Br J Surg
; 110(11): 1490-1501, 2023 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37478362
6.
Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action.
Gastric Cancer
; 26(6): 958-968, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382783
7.
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study.
Future Oncol
; 19(23): 1601-1611, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37577810
8.
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lancet Oncol
; 23(7): 876-887, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35636444
9.
Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise.
Oncologist
; 27(2): e158-e167, 2022 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641220
10.
Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study.
Oncologist
; 27(1): e29-e36, 2022 02 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35305093
11.
Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial.
Ann Surg Oncol
; 29(3): 1880-1889, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34855063
12.
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Br J Cancer
; 124(1): 183-190, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33024268
13.
Treatment personalization in gastrointestinal neuroendocrine tumors.
Curr Treat Options Oncol
; 22(4): 29, 2021 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33641005
14.
Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.
Future Oncol
; 17(18): 2315-2324, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33663264
15.
Correction: miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
Br J Cancer
; 122(10): 1576, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32303716
16.
miR-27a is a master regulator of metabolic reprogramming and chemoresistance in colorectal cancer.
Br J Cancer
; 122(9): 1354-1366, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32132656
17.
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
Oncologist
; 25(6): e928-e935, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31943506
18.
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
BMC Cancer
; 20(1): 822, 2020 Aug 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-32867715
19.
AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
BMC Cancer
; 20(1): 683, 2020 Jul 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32698790
20.
CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer.
Br J Cancer
; 121(7): 593-599, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31474758